type 2 diabetes glp-1 GLP-1-based therapies for diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome All Your Questions About GLP-1s

Clinical studies demonstrate that consistent GLP-1 therapy can result in 1020% body weight reduction , alongside improved blood sugar and lipid profiles

however, first-time prescribing rates declined over the same period (-6.6%)

Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in china

Switching Between Them: From Mounjaro to Semaglutide: Take last Mounjaro dose Wait one week Start semaglutide at 0.5-1.0 mg (provider determines dose) Adjust based on response From Semaglutide to Tirzepatide: Take last semaglutide dose Wait one week Start tirzepatide at 2.5-5 mg (provider determines dose) Escalate according to standard protocol Switching is safe and common

The database collects anonymized longitudinal patient data from a network of general practitioner practices across the UK